Alembic Pharmaceuticals Limited

NSEI:APLLTD Stock Report

Market Cap: ₹170.8b

Alembic Pharmaceuticals Valuation

Is APLLTD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of APLLTD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: APLLTD (₹902.55) is trading above our estimate of fair value (₹689.24)

Significantly Below Fair Value: APLLTD is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for APLLTD?

Other financial metrics that can be useful for relative valuation.

APLLTD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.8x
Enterprise Value/EBITDA18.7x
PEG Ratio1.6x

Price to Earnings Ratio vs Peers

How does APLLTD's PE Ratio compare to its peers?

The above table shows the PE ratio for APLLTD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average59.3x
SUVENPHAR Suven Pharmaceuticals
59.3x19.9%₹181.7b
500674 Sanofi India
28.6x11.9%₹159.3b
CONCORDBIO Concord Biotech
51.7x22.9%₹163.2b
506820 AstraZeneca Pharma India
97.8xn/a₹158.8b
APLLTD Alembic Pharmaceuticals
28.8x17.6%₹170.8b

Price-To-Earnings vs Peers: APLLTD is good value based on its Price-To-Earnings Ratio (28.8x) compared to the peer average (59.3x).


Price to Earnings Ratio vs Industry

How does APLLTD's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.1%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.1%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: APLLTD is good value based on its Price-To-Earnings Ratio (28.8x) compared to the Indian Pharmaceuticals industry average (32.8x).


Price to Earnings Ratio vs Fair Ratio

What is APLLTD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

APLLTD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio28.8x
Fair PE Ratio33.1x

Price-To-Earnings vs Fair Ratio: APLLTD is good value based on its Price-To-Earnings Ratio (28.8x) compared to the estimated Fair Price-To-Earnings Ratio (33.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst APLLTD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹902.55
₹983.54
+9.0%
9.8%₹1,229.00₹845.00n/a13
Jun ’25₹923.10
₹980.31
+6.2%
10.1%₹1,229.00₹845.00n/a13
May ’25₹999.60
₹937.69
-6.2%
9.7%₹1,143.00₹770.00n/a13
Apr ’25₹1,008.95
₹901.08
-10.7%
7.3%₹1,023.00₹770.00n/a13
Mar ’25₹1,055.00
₹888.14
-15.8%
8.9%₹1,023.00₹720.00n/a14
Feb ’25₹955.55
₹769.67
-19.5%
13.0%₹915.00₹515.00n/a15
Jan ’25₹765.90
₹742.44
-3.1%
15.2%₹915.00₹515.00n/a16
Dec ’24₹751.15
₹742.44
-1.2%
15.2%₹915.00₹515.00n/a16
Nov ’24₹712.55
₹723.07
+1.5%
15.1%₹895.00₹515.00n/a15
Oct ’24₹784.45
₹715.33
-8.8%
14.9%₹895.00₹515.00n/a15
Sep ’24₹770.50
₹715.33
-7.2%
14.9%₹895.00₹515.00n/a15
Aug ’24₹775.50
₹598.20
-22.9%
9.0%₹704.00₹515.00n/a15
Jul ’24₹636.40
₹590.87
-7.2%
8.7%₹704.00₹515.00n/a15
Jun ’24₹548.85
₹586.94
+6.9%
8.7%₹704.00₹515.00₹923.1016
May ’24₹556.15
₹601.25
+8.1%
7.7%₹704.00₹540.00₹999.6016
Apr ’24₹496.35
₹603.44
+21.6%
7.3%₹704.00₹540.00₹1,008.9516
Mar ’24₹507.25
₹630.24
+24.2%
14.5%₹944.00₹550.00₹1,055.0017
Feb ’24₹539.65
₹674.63
+25.0%
14.1%₹944.00₹563.00₹955.5516
Jan ’24₹572.90
₹676.50
+18.1%
14.2%₹944.00₹563.00₹765.9016
Dec ’23₹594.60
₹682.75
+14.8%
13.4%₹944.00₹563.00₹751.1516
Nov ’23₹577.85
₹681.44
+17.9%
14.0%₹944.00₹538.00₹712.5516
Oct ’23₹604.65
₹693.53
+14.7%
12.8%₹944.00₹590.00₹784.4517
Sep ’23₹642.30
₹693.53
+8.0%
12.8%₹944.00₹590.00₹770.5017
Aug ’23₹705.05
₹810.00
+14.9%
12.2%₹1,040.00₹629.00₹775.5017
Jul ’23₹729.90
₹819.00
+12.2%
11.3%₹1,040.00₹665.00₹636.4017
Jun ’23₹722.45
₹811.19
+12.3%
11.1%₹1,040.00₹665.00₹548.8516

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.